News BMS adds to IBD pipeline with $1.9bn GentiBio deal Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel (Treg) therapies for inflammatory bowel disease (IBD).
R&D Modelling biologics: Challenges and opportunities, with Dr D... From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.